Abeona Reports Strong ZEVASKYN Revenue Growth, In-licenses Novel Oncology Asset
ABEO sits 46% above its 52-week low of $4.
Summary
Abeona Therapeutics reported strong Q1 2026 revenue growth for ZEVASKYN and expanded its pipeline by in-licensing a novel T-cell therapy for prostate cancer, signaling strategic focus and commercial traction.
Key Events · Earnings and Guidance · ABEO
-
Q1 2026 Revenue Growth
Net product revenue for ZEVASKYN increased to $8.7 million in Q1 2026, up from $2.4 million in Q4 2025, demonstrating commercial traction.
-
New Oncology Pipeline Asset
The company in-licensed ABO-701, a novel engineered T-cell therapy for advanced prostate cancer, for a $7.0 million upfront payment, with an Investigational New Drug (IND) application expected in the second half of 2027.
-
ZEVASKYN Commercial Expansion
The qualified treatment center (QTC) network expanded to six sites, and patient access grew with published coverage policies now in place for 95% of commercially insured U.S. lives.
-
Strategic Portfolio Optimization
Abeona deprioritized its in-house ophthalmology programs to focus resources on ZEVASKYN commercialization and the new ABO-701 oncology program.
Analysis · ABEO · Life Sciences
Abeona Therapeutics reported its first-quarter 2026 financial results, highlighting significant commercial momentum for its gene therapy, ZEVASKYN, with a substantial increase in product revenue. The company also made a strategic move by in-licensing ABO-701, a novel engineered T-cell therapy for advanced prostate cancer, involving a $7.0 million upfront payment. This expands their pipeline into a high-value oncology area, while they deprioritize ophthalmology programs to focus resources.
At the time of this filing, ABEO was trading at $5.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324M. The 52-week trading range was $4.00 to $7.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.